BIOQUÉBEC, MONTRÉAL INVIVO AND SHERBROOKE INNOPOLE JOIN THEIR VOICES IN A LETTER ADDRESSED TO THE PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB)
BIOQuébec, Montréal InVivo and Sherbrooke Innopole request the postponement of the coming into force of the new PMPRB guidelines
On December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.
In parallel and at the national level, on December 6th, 2022, BIOQuébec co-signed a letter addressed to the Honorable Jean-Yves Duclos, Minister of Health of Canada and to the Honorable François-Philippe Champagne, Minister of Innovation, Science and Industry Canada, in partnership with BIOTECanada and other Canadian life science associations. The purpose of this letter was to express the deep concerns of the Canadian biotechnology innovation sector with the PMPRB's proposed guidelines for the Patented Medicines Regulations. Organizations have thus expressed their opinion on the risks of a very adverse impact on the investment decisions of organizations in our sector. The cosigners invited relevant government departments to please work with Canada's biotechnology sector to strengthen, not weaken, the national ecosystem in pursuit of the goals set out in the Biomanufacturing Strategy and of life sciences.